$4.17
-0.13(-2.91%)
Mkt Cap $575.1K
$3.73
$28.80
52-Week Range
At a Glance
AI-generatedPurple Biotech Ltd., a clinical-stage biotech firm, reported a net loss of $26.5 million for FY 2025, up from $7.3 million in FY 2024, driven by a $20.5 million impairment loss on intangible assets related to CM24 and NT219 programs.
6-K
Purple Biotech Ltd. announced a collaboration with Converge Bio to leverage proprietary generative AI for accelerating development of its next-generation tri-specific antibody platform. The partnership aims to reduce discovery timelines, enhance molecule quality, and target solid tumors, building on the CAPTN-3 platform.$575.1K
Market Cap
—
Revenue
-$13.0K
Net Income
Employees9
Fundamentals
How The Business Makes Money
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
Industry Biotechnology
Activity
What Changed Recently
Company Profile
CIK0001614744
ISINUS74638P2083
CUSIP74638P109
Phone972 3 933 3121
Address4 Oppenheimer Street, Rehovot, 7670104, IL
SEC EDGAR